[{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"EMD Serono","sponsor":"GORTEC | Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"EMD Serono \/ GORTEC | Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ GORTEC | Merck Group"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Xevinapant","moa":"||DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":1.0700000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.0700000000000001,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Merck & Co"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xevinapant","moa":"||DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO","graph1":"Undisclosed","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck Group \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Merck Group"},{"orgOrder":0,"company":"University of Chicago","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO","graph1":"Oncology","graph2":"Phase I","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Chicago \/ EMD Serono","highestDevelopmentStatusID":"6","companyTruncated":"University of Chicago \/ EMD Serono"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO","graph1":"Oncology","graph2":"Phase I","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moffitt Cancer Center \/ EMD Serono","highestDevelopmentStatusID":"6","companyTruncated":"Moffitt Cancer Center \/ EMD Serono"},{"orgOrder":0,"company":"GORTEC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO","graph1":"Oncology","graph2":"Phase III","graph3":"GORTEC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GORTEC \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GORTEC \/ Inapplicable"},{"orgOrder":0,"company":"European Organisation for Research and Treatment of Cancer","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Xevinapant","moa":"DIABLO","graph1":"Oncology","graph2":"Phase II","graph3":"European Organisation for Research and Treatment of Cancer","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"European Organisation for Research and Treatment of Cancer \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"European Organisation for Research and Treatment of Cancer \/ Merck Group"}]

Find Clinical Drug Pipeline Developments & Deals for Xevinapant

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Debio 1143 (xevinapant) is an investigational potent oral small-molecule IAP inhibitor. It is being evaluated for the treatment of locally advanced squamous cell carcinoma of the head and neck.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 24, 2024

                          Lead Product(s) : Xevinapant,Cisplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 17, 2024

                          Lead Product(s) : Xevinapant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : EMD Serono

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University of Chicago

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          University of Chicago

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 31, 2023

                          Lead Product(s) : Xevinapant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : EMD Serono

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 28, 2023

                          Lead Product(s) : Xevinapant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Merck Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          GORTEC

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          GORTEC

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 05, 2023

                          Lead Product(s) : Xevinapant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          European Organisation for Research and Treatment of Cancer

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          European Organisation for Research and Treatment of Cancer

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 13, 2023

                          Lead Product(s) : Xevinapant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Merck Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 29, 2022

                          Lead Product(s) : Xevinapant

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Merck Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Xevinapant (formerly known as Debio 1143) is an investigational first-in-class potent oral small-molecule IAP (inhibitor of apoptosis protein) inhibitor for the treatment of LA SCCHN.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 09, 2022

                          Lead Product(s) : Xevinapant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Merck Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 23, 2022

                          Lead Product(s) : Xevinapant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Merck Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 15, 2021

                          Lead Product(s) : Xevinapant

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank